AngioDynamics (NASDAQ:ANGO) Releases Earnings Results, Beats Expectations By $0.13 EPS

AngioDynamics (NASDAQ:ANGO) released its earnings results on Thursday. The medical instruments supplier reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.13, FiscalAI reports. The firm had revenue of $78.42 million for the quarter, compared to the consensus estimate of $76.77 million. AngioDynamics had a negative net margin of 9.02% and a negative return on equity of 2.28%.

Here are the key takeaways from AngioDynamics’ conference call:

• AngioDynamics reported Q3 revenue of $78.4M, up 8.9% YoY with MedTech up 19%, and raised FY26 net sales guidance to $313.5–$315.5M and adjusted EBITDA to $10–$12M (third consecutive upward revision).
• Auryon delivered its nineteenth consecutive quarter of double‑digit growth as increased hospital adoption and product line extensions (radial access, 1.7 mm catheters) drive volume and improved pricing dynamics.
• The combined mechanical thrombectomy portfolio (AlphaVac + AngioVac) grew ~18% YoY, with AlphaVac +47% YoY and +24% sequential, and the company has enrolled first patients in the pivotal APEX‑Return trial targeting approval in Q1 2027.
• NanoKnife revenue rose 21% (capital +24.9%, probes +20%), supported by the Jan 1 implementation of a CPT Category I code and expanded European indications that should boost capital placements and probe utilization.
• Gross margin fell 110 bps to 52.9% due to tariffs, inflation, and a manufacturing transition; tariffs were $1.3M in Q3 and are expected to be $4–$6M for FY26, and a planned $3–$5M inventory build for sterilization shutdowns could make FY26 cash flow slightly negative despite expected strong Q4 cash generation.

AngioDynamics Price Performance

AngioDynamics stock traded down $0.42 during mid-day trading on Thursday, reaching $11.52. The stock had a trading volume of 405,759 shares, compared to its average volume of 553,110. AngioDynamics has a one year low of $8.36 and a one year high of $13.99. The company has a 50-day moving average price of $10.86 and a two-hundred day moving average price of $11.55. The company has a market capitalization of $474.90 million, a price-to-earnings ratio of -17.43 and a beta of 0.43.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Kotler Kevin bought a new position in AngioDynamics during the fourth quarter valued at approximately $21,997,000. UBS Group AG grew its position in AngioDynamics by 83.6% in the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after purchasing an additional 501,881 shares during the period. Millennium Management LLC raised its stake in AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the last quarter. Nuveen LLC lifted its holdings in shares of AngioDynamics by 40.5% during the 4th quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after buying an additional 373,110 shares during the period. Finally, State Street Corp lifted its holdings in shares of AngioDynamics by 33.0% during the 4th quarter. State Street Corp now owns 1,272,735 shares of the medical instruments supplier’s stock valued at $16,342,000 after buying an additional 315,844 shares during the period. 89.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ANGO shares. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.